C:\Program Files\Stnexp\Queries\10694561.





chain nodes :
10 11 12 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
1-20 2-11 4-10 11-12 12-17 20-21 21-22 21-23 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 1-20 2-3 2-11 3-4 4-5 4-10 5-6 5-7 6-9 7-8 8-9 11-12
21-22 21-23 23-24
exact bonds :
12-17 20-21
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
18:Atom 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

=>
Uploading C:\Program Files\Stnexp\Queries\10694561.str



chain nodes :
10 11 12 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
1-20 2-11 4-10 11-12 12-17 20-21 21-22 21-23 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-20 2-3 2-11 3-4 4-5 4-10 5-6 5-7 6-9 7-8 8-9 11-12 21-22
21-23 23-24
exact bonds :
12-17 20-21
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 20:11:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     34 TO ITERATE

100.0% PROCESSED      34 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          331 TO     1029
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 20:11:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    612 TO ITERATE

100.0% PROCESSED     612 ITERATIONS                              29 ANSWERS
SEARCH TIME: 00.00.01

L3           29 SEA SSS FUL L1

=> => s l3
L4            6 L3

=> d l4 1-6 bib,ab,hitstr
```

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:720873 CAPLUS
DN 141:342698
TI SB-480848 (GlaxoSmithKline)
AU Rotella, David P.
CS Lexicon Pharmaceuticals, Princeton, NJ, 08540, USA
SO Current Opinion in Investigational Drugs (Thomson Scientific) (2004), 5(3), 348-351
CODEN: COIDAZ; ISSN: 1472-4472
PB Thomson Scientific
DT Journal; General Review
LA English
AB A review. SB-480848 (synonyms/analogs: SB-435445, Lp-PLA2 inhibitor) is a reversible lipoprotein-associated phospholipase A2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.
IT **356057-34-6P**, SB 480848
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SB 435445; reversible lipoprotein-associated phospholipase A2 inhibitor SB-480848 for potential treatment of atherosclerosis)
RN 356057-34-6 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:837075 CAPLUS
DN 139:337982
TI Preparation of pyridone and pyrimidone compounds as inhibitors of the enzyme Lp-PLA2
IN Leach, Colin Andrew; Smith, Stephen Allan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087088	A2	20031023	WO 2003-GB1550	20030410
	WO 2003087088	A3	20040108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-8280 A 20020410
OS MARPAT 139:337982
AB The title compds. [I; R1 = (un)substituted aryl; R2 = halo, alkyl, alkoxy, etc.; R3 = H, halo, alkyl, hydroxyalkyl; R2 and R3 together with the pyridone or pyrimidine ring carbons to which they are attached form (un)substituted fused 5-6 membered carbocyclic ring, fused benzo or heteroaryl ring; R4 = (CH2)n substituted by benzimidazole or 5-6 membered heteroaryl; R5 = (un)substituted (hetero)aryl; R6 = (un)substituted (hetero)aryl; X = CH, N; Y = alkylene, CH:CH, (CH2)mS; n = 1-4; m = 1-2] that are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis, were prepared Thus, amidation of 2-[2-(2,3-difluorobenzylthio)-4-oxo-4H-quinolin-1-yl]acetic acid with N-[2-(1-methylimidazol-4-yl)ethyl]-4'-trifluoromethylbiphen-4-ylmethylamine (prepns. given) afforded the quinolinone II. The exemplified compds. I showed IC50 values in the range <0.1 to 100 nM against Lp-PLA2.
IT **615578-19-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridone compds. as inhibitors of the enzyme Lp-PLA2)
RN 615578-19-3 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:836853 CAPLUS
DN 139:337978
TI Preparation of N-substituted pyridinone and pyrimidinone derivatives for use as Lp-PLA2 inhibitors in the treatment of atherosclerosis
IN Leach, Colin Andrew; Smith, Stephen Allan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003086400	A1	20031023	WO 2003-GB1544	20030410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-8279 A 20020410
OS MARPAT 139:337978
AB The title compds. [I; R1 = (un)substituted aryl; R2 = halo, alkyl, alkoxy, etc.; R3 = H, halo, alkyl, hydroxyalkyl; R2 and R3 together with the pyridone or pyrimidone ring carbons to which they are attached form (un)substituted fused 5-6 membered carbocyclic ring, fused benzo or heteroaryl ring; R4 = alkyl substituted by 5-7 membered saturated heterocyclyl comprising N and optionally O or S; R5 = (un)substituted (hetero)aryl; R6 = (un)substituted (hetero)aryl; X = CH, N; Y = alkylene, CH:CH, (CH2)nS; n = 1-3] that are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis, were prepared Thus, amidation of 2-[2-(2,3-difluorobenzylthio)-4-oxo-4H-quinolin-1-yl]acetic acid with N-(1-thiazol-2-ylmethylpiperidin-4-yl)-4'-trifluoromethylbiphen-4-ylmethylamine (prepns. given) afforded the quinolinone II. The exemplified compds. I showed IC50 values in the range <0.1 to 100 nM against Lp-PLA2.
IT **615577-22-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinone and pyrimidinone derivs. for use as Lp-PLA2 inhibitors in the treatment of atherosclerosis)
RN 615577-22-5 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:215748 CAPLUS
DN 139:78433
TI The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2
AU Blackie, Josie A.; Bloomer, Jackie C.; Brown, Murray J. B.; Cheng, Hung-Yuan; Hammond, Beverley; Hickey, Deirdre M. B.; Ife, Robert J.; Leach, Colin A.; Lewis, V. Ann; Macphee, Colin H.; Milliner, Kevin J.; Moores, Kitty E.; Pinto, Ivan L.; Smith, Stephen A.; Stansfield, Ian G.; Stanway, Steven J.; Taylor, Maxine A.; Theobald, Colin J.
CS Medicines Research Centre, GlaxoSmithKline, Stevenage, SG1 2NY, UK
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(6), 1067-1070
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:78433
AB Modification of the pyrimidone 5-substituent in clin. candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A2 with sub-nanomolar potency. Cyclopentyl fused derivative 21, SB-480848, showed an enhanced in vitro and in vivo profile vs. SB-435495 and has been selected for progression to man.
IT **552857-62-2P 552857-63-3P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design and structure activity of lipoprotein-associated phospholipase A2 inhibitor SB-480848)
RN 552857-62-2 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-(2-aminoethyl)-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 552857-63-3 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-(2-aminoethyl)-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:154411 CAPLUS
DN 138:187787
TI Novel processes for the preparation of pyrimidinone derivatives, useful as Lp-PLA2 inhibitors, and intermediates thereof
IN Mulholland, Keith Raymond; Ross, Andrew R.; Slater, Graham Ralph; Smith, Gillian Elizabeth
PA Smithkline Beecham PLC, UK
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English

Common Assignee

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016287	A2	20030227	WO 2002-EP9067	20020813
	WO 2003016287	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1456183	A2	20040915	EP 2002-794787	20020813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2004242875	A1	20041202	US 2004-485972	20040702
PRAI	GB 2001-19795	A	20010814		
	WO 2002-EP9067	W	20020813		

Check

OS CASREACT 138:187787; MARPAT 138:187787

AB The invention relates to a process for the preparation of certain pyrimidinone compds., including the intermediates I and II [wherein: RaRb = (CH2)3-4; R1 = Ph optionally substituted by halogen], and the final target compds. III [wherein: RaRb = atoms to form 5-membered carbocyclic ring; R1 = 4-fluorophenyl; R2 = C1-3 alkyl substituted by NR5R6; R2 = Het-C0-2-alkyl; Het = 5- to 7-membered N-heterocyclyl with N optionally substituted by C1-6 alkyl; R3R4 = 4-[4-(trifluoromethyl)phenyl]phenyl; R5, R6 = H, C1-6 alkyl]. Compds. III, described in WO 01/60805, are known inhibitors (no data) of lipoprotein-associated phospholipase A2 (Lp-PLA2), useful, e.g., for prevention of acute coronary events caused by atherosclerosis. The literature methods of preparing III suffer from moderate yields due to poor selectivity in the alkylation of the pyrimidinone nucleus. The invention method gives selective N1-alkylation of the pyrimidinone nucleus, and does not require isolation of an intermediate ester, thus giving high yields and efficiency. For instance, cyclocondensation of Et 2-oxocyclopentanecarboxylate with thiourea in the presence of DBU gave 67.6% 5,6-trimethylene-2-thiouracil, which underwent S-alkylation by 4-fluorobenzyl chloride in the presence of K2CO3 and KI in Me2CO to give 86.5% intermediate II [R1 = 4-FC6H4, RaRb = (CH2)3]. This compound was selectively O-silylated by (Me3Si)2NH and saccharin in CH2Cl2, selectively N1-alkylated by CF3SO2OCH2CO2Me, and then hydrolyzed directly by aqueous NaOH in iso-PrOH, to give 69% I [R1 = 4-FC6H4, RaRb = (CH2)3]. Amidation of this acid with the corresponding amine using DIPEA and TBTU in CH2Cl2, followed by recrystn. from iso-PrOAc, gave 88% target compound IV.

IT **356057-34-6P**, 1-[[[N-[2-(Diethylamino)ethyl]-N-[4-[4-(trifluoromethyl)phenyl]benzyl]amino]carbonyl]methyl]-2-(4-fluorobenzylthio)-5,6-trimethylenepyrimidin-4-one
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(product; processes for preparation of pyrimidinone derivs. useful as Lp-PLA2 inhibitors and their intermediates)

RN 356057-34-6 CAPLUS

CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:617985 CAPLUS
DN 135:195570
TI Preparation of pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
IN Hickey, Deirdre Mary Bernadette; Ife, Robert John; Leach, Colin Andrew; Pinto, Ivan Leo; Smith, Stephen Allan; Stanway, Steven James
PA Smithkline Beecham P.L.C., UK
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English

Appl PCT

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060805	A1	20010823	WO 2001-EP1515	20010213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2400554	AA	20010823	CA 2001-2400554	20010213
	AU 2001035466	A5	20010827	AU 2001-35466	20010213
	EP 1263740	A1	20021211	EP 2001-907522	20010213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008396	A	20030311	BR 2001-8396	20010213
	JP 2003523335	T2	20030805	JP 2001-560190	20010213
	NZ 520752	A	20040326	NZ 2001-520752	20010213
	RU 2235722	C2	20040910	RU 2002-124611	20010213
	US 2002103213	A1	20020801	US 2001-782930	20010214
	TW 550259	B	20030901	TW 2001-90103332	20010215
	NO 2002003828	A	20020930	NO 2002-3828	20020813
	ZA 2002006528	A	20030313	ZA 2002-6528	20020815
	BG 107034	A	20030430	BG 2002-107034	20020826
	US 6649619	B1	20031118	US 2003-357238	20030203
	US 2004097525	A1	20040520	US 2003-694561	20031027
PRAI	GB 2000-3636	A	20000216		
	GB 2001-1437	A	20010119		
	WO 2001-EP1515	W	20010213		
	US 2001-782930	B1	20010214		
	US 2003-357238	A3	20030203		

OS MARPAT 135:195570

AB The title compds. [I; Ra = H, halo, alkyl, etc.; Rb = H, halo, alkyl, etc.; Ra and Rb together = (CH2)n (n = 3-4) or Ra and Rb together with the pyrimidine ring carbon atoms to which they are attached form (un)substituted fused benzo or heteroaryl ring; Rc = H, alkyl; R2 = (un)substituted (hetero)aryl; R3 = H, alkyl, halo, etc.; R4 = (un)substituted (hetero)arylene; R5 = (un)substituted (hetero)aryl; n = 1-4; X = O, S; Y = (CH2)pOq (p = 1-3 and q = 0; p = 2-3 and q = 1); Z = O, a bond] which are inhibitors of the enzyme Lp-PLA2 useful in treating atherosclerosis, were prepared Thus, reacting N-[2-(diethylamino)ethyl]-4-(4-trifluoromethylphenyl)benzylamine with 1-(carboxymethyl)-2-(4-fluorobenzylthio)-5-ethylpyrimidin-4-one in the presence of HATU and (iso-Pr)2NEt in CH2Cl2 afforded the pyrimidinone II. The compds. I

described in Examples were tested for Lp-PLA2 inhibition and showed IC50 values in the range <0.1 nM to 10 μM.

IT **356057-38-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrimidine-4-one derivs. as LDL-PLA2 inhibitors)

RN 356057-38-0 CAPLUS

CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 356057-37-9

CMF C35 H37 F4 N5 O2 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT **356057-34-6P 356057-35-7P 356057-36-8P**
356057-37-9P 356057-39-1P 356057-40-4P
356057-69-7P 356057-87-9P 356057-88-0P
356057-89-1P 356057-90-4P 356057-91-5P
356057-92-6P 356057-93-7P 356057-94-8P
356057-95-9P 356057-98-2P 356057-99-3P
356058-00-9P 356058-03-2P 356058-05-4P
356058-06-5P 356058-07-6P 356058-12-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine-4-one derivs. as LDL-PLA2 inhibitors)

RN 356057-34-6 CAPLUS

CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-35-7 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 356057-34-6
CMF C36 H38 F4 N4 O2 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 356057-36-8 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-

fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 356057-37-9 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-39-1 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-40-4 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 356057-39-1
CMF C34 H36 F4 N6 O2 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 356057-69-7 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[(4'-chloro[1,1'-biphenyl]-4-

yl)methyl]-N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-87-9 CAPLUS

CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(2,3-difluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-88-0 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(3,4-difluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-89-1 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-2-[[(2,3,4-trifluorophenyl)methyl]thio]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-90-4 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(2-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-91-5 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-N-methyl-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-92-6 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[2-(1-piperidinyl)ethyl]-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-93-7 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[3-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 356057-94-8 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-95-9 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-98-2 CAPLUS

CN 1H-Cyclopentapyrimidine-1-acetamide, N-(1-ethyl-4-piperidinyl)-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356057-99-3 CAPLUS

CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(ethylamino)-2-methylpropyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356058-00-9 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-[(1,1-dimethylethyl)amino]ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356058-03-2 CAPLUS
CN Carbamic acid, [2-[[[2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-1H-cyclopentapyrimidin-1-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356058-05-4 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-N-(1-methyl-4-piperidinyl)-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356058-06-5 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-N-[1-(1-methylethyl)-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356058-07-6 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-N-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 356058-12-3 CAPLUS
CN 1H-Cyclopentapyrimidine-1-acetamide, N-[2-(ethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 20:10:35 ON 07 DEC 2004)

     FILE 'REGISTRY' ENTERED AT 20:10:39 ON 07 DEC 2004
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3             29 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 20:11:23 ON 07 DEC 2004
L4              6 S L3

     FILE 'CAOLD' ENTERED AT 20:11:50 ON 07 DEC 2004

=> s l3
L5              0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42     185.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.20

STN INTERNATIONAL LOGOFF AT 20:12:01 ON 07 DEC 2004
```